Multiple Myeloma (MM)

Oncology
3
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
ABBV-467Phase 11 trial
Active Trials
NCT04178902Terminated8Est. Apr 2021
Leman Biotech
Leman BiotechChina - Shenzhen
1 program
1
Metabolically Armed BCMA CAR-T cells.Phase 1Cell Therapy1 trial
Active Trials
NCT07085559RecruitingEst. Oct 2027
Novartis
NovartisBASEL, Switzerland
1 program
1
WVT078Phase 11 trial
Active Trials
NCT04123418Terminated56Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Leman BiotechMetabolically Armed BCMA CAR-T cells.
AbbVieABBV-467
NovartisWVT078

Clinical Trials (3)

Total enrollment: 64 patients across 3 trials

NCT07085559Leman BiotechMetabolically Armed BCMA CAR-T cells.

Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

Start: Jun 2025Est. completion: Oct 2027
Phase 1Recruiting

A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma

Start: May 2020Est. completion: Apr 20218 patients
Phase 1Terminated

A Study of WVT078 in Patients With Multiple Myeloma (MM)

Start: Dec 2019Est. completion: Dec 202456 patients
Phase 1Terminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 64 patients
3 companies competing in this space